文献速递银屑病与炎症性皮肤病

Picankibart治疗中重度斑块状银屑病的多中心随机双盲安慰剂对照III期试验

A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2026-04-03

CLEAR-1研究纳入中国中重度斑块状银屑病患者,随机接受picankibart 200mg不同方案或安慰剂,主要终点为第16周PASI≥90和sPGA 0/1。结果显示200mg组PASI≥90达80.3%、sPGA 0/1达93.5%,显著优于安慰剂,疗效维持至第52周且无新安全性信号。

要点

  • Picankibart 200mg组第16周PASI≥90应答率80.3%,sPGA 0/1应答率93.5%。
  • 安慰剂组第16周PASI≥90应答率2.0%,sPGA 0/1应答率13.1%。
  • 100mg或200mg每12周给药方案可维持疗效至第52周。

核心结论

  • Picankibart在中国中重度斑块状银屑病患者中第16周即可提供有效的皮损清除。
  • 每12周给予100mg或200mg可维持临床改善至第52周,未观察到新的安全性信号。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照III期试验(CLEAR-1),纳入18-75岁中国中重度斑块状银屑病患者。
  • 患者随机接受picankibart 200mg(第0/4/8/20/32/44周)、picankibart 200mg(第0/4/8周)后100mg(第20/32/44周),或安慰剂(第0/4/8周)后picankibart 200mg(第16/20/24/32/44周)。
  • 共同主要终点为第16周PASI≥90改善和sPGA 0/1(清除/几乎清除)。

主要发现

  • Picankibart 200mg组第16周80.3%达到PASI≥90,93.5%达到sPGA 0/1;安慰剂组分别为2.0%和13.1%。
  • 所有关键次要终点均显著改善(双侧P < .0001 vs 安慰剂)。
  • 100mg和200mg剂量组疗效维持至第52周,未观察到新的安全性信号。

关键数值与推荐

  • 共同主要终点:第16周PASI≥90和sPGA 0/1。
  • Picankibart 200mg组第16周PASI≥90应答率80.3%,sPGA 0/1应答率93.5%。
  • 安慰剂组第16周PASI≥90应答率2.0%,sPGA 0/1应答率13.1%。
  • 关键次要终点双侧P < .0001 vs 安慰剂。

临床怎么用

  • Picankibart可作为中国中重度斑块状银屑病的候选生物制剂,第16周评估皮损清除。
  • 每12周100mg或200mg维持方案可能提供长期疗效,需结合患者情况选择。

局限性

  • 研究仅纳入中国患者。
  • 未设阳性对照药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of interleukin-23 inhibitors that offer sustained complete skin clearance with reduced-frequency dosing addresses a significant unmet clinical need in managing moderate-to-severe plaque psoriasis. OBJECTIVE: To evaluate the efficacy and safety of picankibart, an interleukin-23p19 inhibitor, in Chinese patients. METHODS: CLEAR-1 enrolled participants aged 18-75 years to randomly receive picankibart subcutaneously 200 mg at weeks 0/4/8/20/32/44, picankibart 200 mg at weeks 0/4/8 then 100 mg at weeks 20/32/44; or placebo at weeks 0/4/8 then picankibart 200 mg at weeks 16/20/24/32/44. The co-primary endpoints were ≥90% improvement in psoriasis area and severity index and static physician's global assessment clear/almost clear status (0/1) at week 16. RESULTS: In picankibart 200 mg group, 80.3% achieved ≥90% improvement in psoriasis area and severity index and 93.5% achieved static physician's global assessment 0/1 at week 16 vs 2.0% and 13.1%, respectively with placebo. All key secondary endpoints were significantly improved (all two-sided P < .0001 vs placebo). Efficacy was maintained through week 52 for both 100 mg and 200 mg doses, with no new safety signal observed. LIMITATIONS: Chinese only; no active comparator. CONCLUSION: Picankibart provided effective skin clearance in Chinese participants by week 16. A dosing regimen of every 12 weeks with either 100 mg or 200 mg maintained these clinical improvements through week 52.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gao Y, Qin L, Li Y, et al. A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2026. PMID: 41937031. doi:10.1016/j.jaad.2026.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。